In today’s episode, we’ll be interviewing CEO and Chairman of TRYP Therapeutics, Greg Mckee. Thus far, this is one of the most informative conversations I’ve had the pleasure of having about the psychedelic industry, the different segments that could be simultaneously tackled, the challenges and opportunities for many of the players in this industry and much more.

I hope you stay till the end and are able to get some value from this discussion.

TRYP Therapeutics (CSE: TRYP) (OTC: TRYPF), is a pharmaceutical company focused on identifying and developing clinical-stage compounds for orphan diseases and other diseases with high unmet medical needs. Some of the diseases TRYP is addressing are: eating disorders and fibromyalgia (chronic widespread pain) .

TRYP intends to seek approval from FDA to proceed directly into a Phase 2 clinical trial based on existing preclinical and clinical data for the active pharmaceutical ingredients in TRP-8802 and TRP-8803.

Timestamps:
0:00 – Intro
0:40 – TRYP’s mission and Greg Mckee’s personal involvement
2:59 – Expanding on TRYP’s main molecules: TRP 8802 and TRP 8803
8:18 – Expanding on TRYP’s flagship programs: Fibromyalgia and Eating Disorder
14:29 – Clinical trial progress and anticipated start of Phase IIa trials
18:26 – Anticipated commercialization timelines
21:34 – TRYP Therapeutics’ competitive advantage
27:22 – Expected relationship with the traditional pharmaceuticals industry and potential partnerships

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

Pertinent links:
Tryp Therapeutics’ Mission:

Home

Tryp’s pipeline progress:

Pipeline

Follow us on social media! 🙌
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Music from:
www.bensound.com

Video editing: @themyaholy

Check out our Benziga discounts
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

Full Disclosure: This video is for entertainment only and shouldn’t be taken as investment advice, Pursuant to an agreement between The Psychedelic Investor and a third party. The Psychedelic Investor has been hired for a period beginning on 29,06,2021 and ending on 29,06,2021 to publicly disseminate information about (TRYP) via digital communications. We have been paid ($1000) .

Home


CSE: TRYP | OTC: TRYPF

#TRYP #TrypTherapeutics #TrypStock

Similar Posts

New Players, BUY Ratings, Financial Results & MORE ( MINDMED, NUMI, CMPS, MYCO, FTRP, HAVN, DMT)

New Players, BUY Ratings, Financial Results & MORE ( MINDMED, NUMI, CMPS, MYCO, FTRP, HAVN, DMT)

Listen, Videos

There were A LOT OF DEVELOPMENTS THIS WEEK, so strap on your seat belts and let’s dive into what happened this week with: MindMed ( MMED / MNMD / MMQ ), Compass Pathways (CMPS), NUMINUS (NUMI), Fieldtrip Health (FTRP / FTRPF), Mydecine ( MYCO / MYCOF), HAVN Labs
( HAVN / HAVLF), Novamind ( NM / NVMDF), Champignon Brands aka Braxia Scientific
(old ticker :SHRM / new ticker: BRAX / BRAXF), Nova Mentis (NOVA / NMLSF) and Small Pharma (DMT).

Timestamps:
0:00 – Intro
0:54 – MindMed’s (MMED / MNMD) Project Angie Announcement
1:47 – Compass Pathways (CMPS) Q1 Financial Results Date & Business Updates
3:16 – Analyst Coverage and Buy Ratings for CMPS
4:35 – Mydecine ( MYCO / MYCOF) 2020 Financial Results & Business Highlights
9:17 – Numinus Wellness (NUMI) Q2 Financial Results
11:25 – Field Trip Health (FTRP/ FTRPF) Opens more clinics
12:19 – Novamind ( NM / NVMDF) doubling its clinics
14:25 – Champignon Brands (SHRM /SHRMF) changing its named to Braxia Scientific (BRAX / BRAXF)
15:31 – NEW DMT company that began trading on may 6th under the name SMALL PHARMA ( DMT)
17:19 – HAVN Labs (HAVN) opens a new lab in Jamaica
17:50 – Nova Mentis launches a new clinical study using psilocybin to treat autism

Link to MindMed’s Project Angie Press release:
https://mindmed.co/news/press-release/mindmed-announces-project-angie-targeting-the-treatment-of-pain-with-psychedelics/

Link to Compass Pathways Q1 financial Results date:
https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-plc-announce-first-quarter-2021-financial

Link to Compass Pathways (CMPS) analyst ratings: https://www.marketbeat.com/stocks/NASDAQ/CMPS/price-target/

Link to Mydecine ( MYCO/ MYCOF) Full Year 2020 Financial results Plus business updates
https://www.globenewswire.com/news-release/2021/05/03/2221266/0/en/Mydecine-Reports-Full-Year-2020-Financial-Results-and-Provides-Business-Update.html

Link to Numinus (NUMI) Q2 2021 Financial Results:
https://www.newswire.ca/news-releases/numinus-wellness-q2-2021-results-highlighted-by-17-25-million-financing-mindspace-wellbeing-acquisition-and-clinical-trial-collaboration-with-maps-pbc-846735411.html

Link to Field Trip’s (FTPR / FTPRF) 7th Psychedelic-assisted therapy Clinic:
https://psilocybinalpha.com/news/field-trip-health-ltd-announces-opening-of-psychedelic-enhanced-therapy-center-in-houston-locations-of-next-5-field-trip-health-centers

Link to Novamind’s (NM / NVMDF) Ketamine Clinic article:
https://novamind.ca/2021-05-04-novamind-doubles-in-size-adds-four-new-psychedelic-mental-health-clinics/

Link to Champignon Brands ( SHRM/ SHRMF) announcing their name change to Braxia Scientific (BRAX / BRAXF):
https://thedeepdive.ca/champignon-brands-to-change-name-to-braxia-scientific/

Link to Small Pharma ( DMT):
https://psilocybinalpha.com/news/small-pharma-completes-reverse-take-over-transaction

Link to Havn’s (HAVN / HAVLF) Jamaica lab:
https://www.psychedelicfinance.com/articles/havn-labs-jamaica-facility-now-fully-operational

Link to Nova Mentis launching a clinical study to learn more about Autism:
https://psilocybinalpha.com/news/nova-mentis-launches-autism-clinical-study

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌

Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
editing by: @themyaholy
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

#MindMed #Numi #CMPS

Cathie Wood of Ark Invest Comments on Psychedelic Stocks like MindMed “We DON’T Invest In Binaries”

Cathie Wood of Ark Invest Comments on Psychedelic Stocks like MindMed “We DON’T Invest In Binaries”

Listen, Videos

Will Ark Invest (ARKK) and Cathie Wood invest in MindMed ( MMED / MMEDF/ MMQ) or other Psychedelic Stocks? In this episode, Cathie Wood talks to Kevin O’Leary about the potential for psychedelic stocks and MindMed.

Kevin O’Leary is a BIG bull in MindMed, but what does Cathie Wood think? Will Ark invest in MindMed? Well, no. She is clear that Ark does not invest in binary outcomes, which MMED / MMEDF cleary is.

Having said this, the door may be left open for the future, as ARKK invests in Healthcare companies using artifical intellegence, exactly what MindMed’s Albert division is working on. Also, once clinical trial results come in, MindMed will no longer be a binary choice. SO anything is possible.

I hope this little impromptu episode added some life and joy to your live and that you guys found some value in this.

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Email: thepsychedelicinvestor@gmail.com
Facebook: @thepsychedelicinvestor
Music: www.bensound.com
https://benzinga.grsm.io/jameshallifax1834
https://benzinga.grsm.io/thepsychedelicinvestor

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

#MindMed​​​ ​#MindmedNews​​​ #PsychedelicStocks

Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy

Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy

Listen, Videos

Scientists Create A New DMT: Can it Treat Depression? | Psychedelic Therapy

When it comes to treating mental health conditions with psychedelic therapy, one of the most promising compounds is DMT, the main ingredient in the brew ayahuasca. While DMT may have many potential advantages over other similar compounds such as psilocybin, for example, its short duration of effect, the hallucination can be very intense.

It is an open question whether the mental health benefits we see from psychedelic therapy are due to the experience one undergoes when having a hallucination, or whether it comes strictly from the drug’s effects on the brain. If it is the latter, then hypothetically speaking, we could create a version of DMT that does not cause a hallucination.

Enter Psilera Biosciences.

Psilera is a psychedelic medicines company working to create next-generation psychedelics for use in therapeutic settings. Specifically, they aim to create non-psychedelic versions of classical psychedelics such as psilocybin, LSD and DMT.

PSIL-002 is Psilera’s version of non-hallucinogenic DMT. They recently completed a pre-clinical trial in mice that showed that their version of DMT was safe and non-psychedelic. Now they have to show that their version of DMT can treat depression and addiction, starting with alcoholism.

If Psilera’s DMT can treat these mental health conditions equally as well as regular DMT, but without the intense hallucination, then PSIL-002 would probably be the better compound.

It is exciting to see Psilera’s scientists working on answering the following questions:

Can DMT treat depression?
Can psychedelics help with depression?
Can psychedelics help with Mental Health?

Enjoy the episode!
Follow us on social media!
Instagram: @thepsychedelicinvestor
Facebook: @thepsychedelicinvestor
James’ Twitter: @Psy_Invest
Maria’s Twitter (Producer & Editor): @Psy_Holy

Want to collaborate? Send us an email at:
thepsychedelicinvestor@gmail.com

Video editing: @themyaholy @Psy_holy

#DMT #DEPRESSION #PSYCHEDELICTHERAPY

Could This DMT Company Break Through the Addiction Market? [ENTHEON:The Next Big Psychedelic Stock?]

Could This DMT Company Break Through the Addiction Market? [ENTHEON:The Next Big Psychedelic Stock?]

Learn, Videos

Hey guys! Today’s episode of “Could This DMT Company Break Through the Addiction Market?” is a little bit different. We’ll cover a DMT company called Entheon BioMedical Corp, ticker symbol ENBI on the CSE and ENTBF on the OTC market.
Entheon is a company trying to solve addiction through the use of DMT which is why I’ve had my eye on for a while now.
Anyone who has learned anything about DMT knows how interesting this compound is and how much healing potential it may have. DMT is especially interesting to me because of the fact that it is naturally produced in our bodies and because of the anecdotal evidence surrounding its mystical capabilities.
I’ve mentioned that an other videos but I’ll say it again. It was actually through learning about DMT on the Joe Rogan Podcast that launched my interest into the healing potential of psychedelics in general. Specifically, his podcasts with Dennis McKenna were an eye opener that I can genuinely say changed my life, because it led to the creation of this channel.
And one of the reasons I agreed to do this sponsored content was because when doing my research into Entheon, I learned that none other than Dennis McKenna was on the Scientific advisory board of the company, which gave me a boost in confidence.
So in this video we are going to do four things:

First give you a brief rundown on who Entheon is, the investment thesis, and the people behind the company.

Second we are going to take you into the realm of DMT, where we will discuss what DMT even is, people’s experiences on the drug, and the scientific literature that is making the potential for using DMT for healing so exciting.

Third, we will discuss Entheon’s upcoming Clinical trials testing the effectiveness of using DMT to treat addiction.

MindMed (MMED) is also doing clinical trials with DMT so I’m excited to see the results. What do you guys think? Is DMT a better alternative than ibogaine to treat addiction?

I hope you guys found some value in this and I’ll keep you posted for more changes!

Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
Follow us on social media! 🙌
Instagram: @psychedelicinvestor
Facebook: @thepsychedelicinvestor
email: thepsychedelicinvestor@gmail.com
Music: www.bensound.com

DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

The Psychedelic Investor was compensated $1,000 by Future Money Trends for the making of this video on Entheon Biomedical. James (The Psychedelic Investor) does not own a position in Entheon Biomedical and will not open one for at least 30 days after publication of this video.

https://entheonbiomedical.com/
CSE: ENBI | OTCQB: ENTBF

This video was conducted on behalf of Entheon Biomedical, and was funded by Gold Standard Media LLC. For our full disclaimer, please visit: https://www.goldstandardir.com/entheon-biomedical-disclaimer-85/

#MindMed​​​ ​#Entheon​​​ #PsychedelicStocks

Riley Cote – From NHL Enforcer to Psychedelic Therapy Advocate

Riley Cote – From NHL Enforcer to Psychedelic Therapy Advocate

Listen, Podcasts

On this episode of the Psychedelic Spotlight Podcast, our host David Flores catches up with former Philadelphia Flyer and NHL enforcer, Riley Cote who in recent years has become one of the most prominent and outspoken advocates for psychedelics and psychedelic-assisted therapy through his work with the Wake Network and RileyCote.com.